Your AI-Trained Oncology Knowledge Connection!
Zenocutuzumab elicited clinical activity with a tolerable safety profile in patients with advanced non–small cell lung cancer harboring NRG1 fusions, including those with prior afatinib exposure, according to findings from the ongoing, phase 1/2 eNRGy trial.
Steven I. Park, MD, discusses the unique design of the SYMPHONY-1 trial, the importance of enrolling patients to the phase 3 portion of the study, and why tazemetostat in combination with lenalidomide and rituximab could represent an effective and tolerable therapeutic option for frail or older patients with relapsed/refractory follicular lymphoma.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of elranatamab-bcmm for the treatment of adult patients with relapsed/refractory multiple myeloma who were previously treated with 3 or more lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and who experienced disease progression on their last therapy.
Adjuvant treatment with pembrolizumab significantly improved overall survival vs placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions, meeting a key secondary end point of the phase 3 KEYNOTE-564 trial.
Press Release
As the first initiative of an emerging collaboration, Fox Chase Cancer Center has invested in Nucleus RadioPharma, a company specializing in the development and distribution of radiopharmaceuticals, targeted therapies that deliver radiation directly to cancer cells.
On September 20, 2023, with the goal of improving care, the American Oncology Network announced the completion of its business combination with Digital Transformation Opportunities Corp to become a publicly traded entity.
The FDA has approved pembrolizumab (Keytruda) plus gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.
Combining sacituzumab govitecan-hziy and enfortumab vedotin-ejfv was safe, feasible, and produced high and early response rates in patients with treatment-resistant metastatic urothelial cancer.
Two novel antibody-drug conjugates, HS-20089 and SGN-B7H4V, targeting the highly expressed immune checkpoint ligand B7-H4 have demonstrated manageable safety profiles and shown anti-tumor activity in first-in-human dose-escalation portions of phase 1 trials and will move forward to the next portions of the studies.
The FDA has granted a fast track designation to SLS009 for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma.
The FDA has lifted the clinical hold placed on a phase 1 trial evaluating XMT-2056 monotherapy in patients with HER2-high or -low advanced or recurrent solid tumors.
VAL-083 did not improve efficacy compared with standard-of-care approaches in patients with glioblastoma.
The FDA has granted breakthrough therapy designation to furmonertinib for use as a potential therapeutic option in patients with previously untreated, locally advanced or metastatic nonsquamous non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
Igor Astsaturov, MD, PhD, has been appointed inaugural holder of the Paul F. Engstrom Professorship in Oncology.
A closer look at some of the approaches being used across The US Oncology Network to improve patient access can provide helpful insight into how practices can meet the growing need for their services.
Apar Kishor Ganti, MD, discusses molecular targets to test for in lung cancer; treatment approaches for small cell lung cancer; and immunotherapy options for patients with metastatic non–small cell lung cancer in the frontline setting and beyond.
The European Medicines Agency has validated a type II variation application for the first-line combination of nivolumab and cisplatin-based chemotherapy for adult patients with unresectable or metastatic urothelial carcinoma.
The addition of dostarlimab to carboplatin plus paclitaxel followed by dostarlimab monotherapy significantly improved overall survival compared with placebo plus chemotherapy followed by placebo in adult patients with primary advanced or recurrent endometrial cancer.
Vimseltinib elicited a statistically significant and clinically meaningful improvement in 25-week overall response rate vs placebo in patients with tenosynovial giant cell tumor that was not amenable to surgery.
Brexucabtagene autoleucel demonstrated an improvement in overall survival vs standard of care therapy in patients with relapsed/refractory mantle cell lymphoma following prior exposure to a BTK inhibitor, according to data from an indirect treatment comparison of findings from the phase 2 ZUMA-2 trial and retrospective SCHOLAR-2 trial.
BioFlorida, a statewide association for Florida’s life sciences industry, has named Stephen D. Nimer, MD, director of Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, “Researcher of the Year.”
The FDA has granted priority review to a new drug application seeking the approval of tovorafenib monotherapy for the treatment of pediatric patients with relapsed or progressive low-grade glioma.
Postoperative circulating tumor DNA (ctDNA)–based minimal residual disease status demonstrated prognostic value for patients with stage I to IV resected colorectal cancer, showing that those with positive ctDNA after surgery have significantly lower disease-free survival outcomes at 24 months vs those who were ctDNA negative.
Marisol Miranda-Galvis, DDS, MS, PhD, highlights the importance of understanding which social determinants of health have the greatest influence on treatment-related outcomes in patients with hematologic malignancies, expands on key variables identified in a systematic review of these disparities, and emphasizes the importance of continuing to implement new strategies to increase access to quality treatments.
Richard Kim, MD, discusses the range of systemic treatment options available for patients with unresectable hepatocellular carcinoma and the importance of assessing patients for high-risk disease criteria before beginning any systemic treatment.
The FDA has approved toripalimab-tpzi (Loqtorzi) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as monotherapy for the treatment of adult patients with recurrent, unresectable, or metastatic nasopharyngeal carcinoma with disease progression on or after platinum-containing chemotherapy.
Pooled findings from exploratory analyses of the phase 2 DESTINY-Lung01 and DESTINY-Lung02 trials showed that different doses of fam-trastuzumab deruxtecan-nxki elicited similar intracranial responses in patients with HER2-mutated non–small cell lung cancer who had treated or untreated brain metastases at baseline.
Praveen Vikas, MBBS, discusses what is currently known regarding minimal residual disease testing in breast cancer, expanded on what still needs to be done to bring minimal residual disease and ctDNA testing to clinical practice, and highlighted the evolving treatment paradigm for patients with advanced hormone receptor-positive, HER2-negative breast cancer.
The FDA has granted fast track designation to the dual-acting androgen receptor inhibitor ONCT-534 for the treatment of patients with relapsed/refractory, metastatic castration-resistant prostate cancer that is resistant to approved androgen receptor pathway inhibitors.
The European Medicines Agency has accepted a marketing authorization application seeking the approval of mirvetuximab soravtansine-gynx for the treatment of patients with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
